DELIVERING BREAKTHROUGHS
Path to Progress
Novel AAV capsids born from Voyager’s RNA-driven TRACERTM screening platform hold promise to target desired cells and tissues with greater specificity, at lower doses, and with fewer off-target risks than conventional AAV serotypes. TRACER capsids power internal product development and external partnerships with the goal of elevating the field of gene therapy to its highest potential.1
1 Nonnenmacher, et al. “RNA-driven Evolution of AAV Capsid Libraries Identifies Variants with High Transduction Efficiency in Non-Human Primate Central Nervous System.” ASGCT 2021.
Equipped for the Journey
We see each step in our journey as progress toward unlocking the full potential of gene therapy. This is an opportunity to evolve, innovate, and close in on this breakthrough that has enormous promise to change the trajectory of disease and positively alter the lives of millions of people.
In the News
Voyager Therapeutics to Present at the Jefferies Healthcare Conference
CAMBRIDGE, Mass. , June 01, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that CEO Alfred W. Sandrock , Jr., M.D., Ph.D., will present at the Jefferies Healthcare
Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting
Oral presentation features further evaluation of second-generation capsids, demonstrating increased transduction in several brain areas across multiple non-human primate species CAMBRIDGE, Mass. , May 18, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics , Inc. (NASDAQ: VYGR), a biotechnology company
